aristolochic acid I (aristolochic acid)

10/16/2007 - "To study the protective effects of Hirsutella sinensis on renal interstitial fibrosis in chronic aristolochic acid nephropathy (CAAN). "
10/16/2007 - "[Protective effects of Hirsutella sinensis on renal interstitial fibrosis: experiment with rat model of chronic aristolochic acid nephropathy]."
03/01/2008 - "To study the cellular mechanisms contributing to the pathophysiology of this renal disease, we studied Wistar rats treated with aristolochic acid and measured tubular and interstitial cell proliferation, epithelial/mesenchymal cell marker expression, tubular membrane integrity, myofibroblast accumulation, oxidative stress, mitochondrial damage, tubular apoptosis, and fibrosis. "
01/01/2005 - "This study focuses on the chemopreventive effect of five drugs on renal interstitial fibrosis induced by an aristolochic acid-containing Chinese herb Mu-Tong. "
09/25/2001 - "To study chronic renal interstitial fibrosis induced by aristolochic acid (AA) in animal models. "

04/06/2014 - "Bardoxolone methyl (BARD) ameliorates aristolochic acid (AA)-induced acute kidney injury through Nrf2 pathway."
04/06/2014 - "This study aimed to investigate the role of BARD in protecting kidneys from aristolochic acid (AA)-induced acute kidney injury (AKI). "
05/01/2005 - "Recent studies showed that aristolochic acid (AA) could induce acute renal failure and tubular lesions in several species and available evidences demonstrate the unequivocal role of AA in so called Chinese herbs nephropathy. "
07/01/2012 - "Acute renal failure due to an aristolochic acid containing herbal remedy."
11/01/2011 - "Newborn aristolochic acid nephropathy induced by akebia might induce acute renal failure and renal tubules injury. "

09/01/2005 - "However, a significant amount of aristolochic acid (AA) was detected in the consumed Chinese herb mixture (AA-I, 7 microg/g) for the treatment of his leg edema for the past 2 months. "
12/01/1988 - "When aristolochic acid was mixed with HSF-PLA2 and then injected into the mouse foot pad, edema was inhibited in a dose-dependent manner and was positively correlated with in vitro inhibition of PLA2 activity. "
01/01/1987 - "Aristolochic acid inhibits direct and indirect hemolytic activity, as well as edema-inducing activity, of TFV PL-X, but fails to neutralize the lethal potency of the enzyme. "
01/01/1987 - "administration of aristolochic acid following phospholipase injection are equally effective in inhibiting edema. "
06/01/1989 - "The PLA2 inhibitors, luffariellolide and aristolochic acid, reduced the edema but only when coinjected with the PLA2. "

03/26/1966 - "[Improved wound healing and thrombosis prevention following gynecological and obstetrical surgery: clinical experience with a new aristolochic acid containing drug]."

03/01/2015 - "The purpose of this study was to investigate the cancer incidence in patients with end-stage aristolochic acid nephropathy (AAN). "
01/01/2014 - "This study aimed to characterize the TP53 mutational spectrum in urothelial cancers consecutive to Aristolochic Acid Nephropathy in Belgium. "
05/01/2013 - "A meta-analysis of these studies resulted in a pooled OR of 5.97 [95% confidence interval (CI), 2.78-12.84] for this aristolochic acid-related cancer. "
08/18/2015 - "Multifocal tumors, native aristolochic acid nephropathy (AAN) and distal ureter involvement were determined as risk factors for intravesical recurrence by univariate analysis. "
06/15/2015 - "Aristolochic acid (AA) is a potent dietary cytotoxin and carcinogen, and an established etiological agent underlying severe human nephropathies and associated upper urinary tract urothelial cancers, collectively designated aristolochic acid nephropathy (AAN). "